A biotech developing experimental immunotherapies that rewire the body's immune system to fight cancer and autoimmune diseases, with its lead drug Bempegaldesleukin in late-stage trials for melanoma and kidney cancer.
No product sales yet—revenue is tiny (USD 0.06B in 2025) and comes from collaboration payments, while net losses run about USD 0.16B annually, so the business burns cash with no recurring income.
Its drug candidates are protected by patents and deep partnerships with big pharma like Bristol-Myers Squibb and AstraZeneca, but clinical failure risk is high and competitors like Merck and Roche are racing in the same IL-2 space, so the edge is unproven and
Sell (sector percentile 13) — value D-, growth B, profitability C-, momentum B, revisions C. Updated daily, sector-relative, identical for every user.
Key events, in time order
FDA grants single AA Phase 3 path, AtD program doubles as safety database, reducing trials
Q2 loss beat but revenue missed; cash strong; Phase 3 ZENITH-AD underway, data mid-2028
LLY lawyers push for BD/partnership docs post-Feb 2026; pretrial battle intensifies
Quarterly results provide updates on financials and pipeline progress.
Stock gapped from $69.36 to $73.31, reflecting positive market sentiment on Rezpeg prospects
Market mistakenly linked fake ABVX short report to NKTR, causing decline despite broader index gains; M&A thesis unchanged
Cash position exceeds $1 billion after April financing, with $731.6 million in cash and investments at Q1 2026 end plus $351 million from April financing
None yet
None yet
Nektar Therapeutics is involved in a legal dispute with Eli Lilly regarding a potential partnership process for its drug Bempegaldesleukin. The discussion centers on the legal proceedings and information sharing.
Main discussion
interesting development just filed $lly $nktr so as expected $lly chats come in which they tried everything to stop from becoming public/ part of the trial. Flip side $lly got judge to get $nktr to share with $lly since feb 26 whether a rezpeg partnering process is actually under
Upgrades 8/21: $EFX $INNV $MPL $NKTR $OI $POR $PSN $RFIL $STOK $TIC $TX . Downgrades 8/21: $BWMN $FRO $GGB $DOW $DV $HCAT $INNV $LMB $TEF $TER $TX $WB
No comments yet.
Facts and opinions separated · All items sourced · Not investment advice
